Stockwinners Market Radar for November 18, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:43 EST Berkshire Hathaway says berkshirehathawaytx.com has no affiliation with company - "Earlier this afternoon it came to our attention that there is an entity using the name Berkshire Hathaway with a web address of berkshirehathawaytx.com," Berkshire Hathaway said in a statement. "The entity who has this web address has no affiliation with Berkshire Hathaway Inc. or its Chairman and CEO, Warren E. Buffett."

17:36 EST Aptorum Group receives Nasdaq bid price notification - Aptorum Group announced that it received a deficiency letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC notifying the company that, for the last 30 consecutive business days, the closing bid price for the company's Class A Ordinary Shares has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1). The Nasdaq deficiency letter has no immediate effect on the listing of the company's Class A Ordinary Shares, and its Class A Ordinary Shares will continue to trade on The Nasdaq Global Market under the symbol "APM" at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been given 180 calendar days, or until May 16, 2023, to regain compliance with Rule 5450(a)(1). If at any time before May 16, 2023, the bid price of the company's Class A Ordinary Shares closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Staff will provide written confirmation that the company has achieved compliance and the matter will be closed.

17:12 EST Pembina Pipeline announces settlement agreement with Ruby Pipeline - Pembina Pipeline announced that Pembina and certain of its wholly-owned affiliates have entered into a settlement agreement with Ruby Pipeline. The terms of the Settlement Agreement provide for, upon approval of the United States Bankruptcy Court for the District of Delaware and the payment of all amounts contemplated by such agreement, the release of Pembina from any causes of action arising in connection with, among other things, prepetition distributions and the bankruptcy case. In consideration, the Settlement Agreement provides for the payment from Pembina to Ruby of $102M. The United States Bankruptcy Court for the District of Delaware is expected to consider the terms of the Settlement Agreement at a hearing for Ruby's Chapter 11 plan proposed for January 23, 2023. The Plan provides for the potential sale by auction of Ruby's assets with a distribution of the value of the Ruby estate to its creditors following confirmation of the Plan. In the event the Plan is approved as currently contemplated, Pembina's affiliates retain all rights to recovery under the 2026 Subordinated Notes as a creditor, subject to the terms of the Plan and the Sub Notes, after accounting for any rights of subordination in favor of other creditors.

17:06 EST INSU Acquisition Corp. III to redeem shares, won't consummate combination - INSU Acquisition Corp. III announced that, because the company will not consummate an initial business combination within the time period required by its Amended and Restated Certificate of Incorporation, the company intends to dissolve and liquidate in accordance with the provisions of the Charter, effective as of the close of business on December 22, 2022, and will redeem all of the outstanding shares of Class A common stock that were included in the units issued in its initial public offering, at a per-share redemption price of approximately $10.09. As of the close of business on December 22, the Public Shares will be deemed cancelled and will represent only the right to receive the redemption amount. The redemption of the Public Shares is expected to be completed within ten business days after December 2. The company's sponsors have agreed to waive their redemption rights with respect to their outstanding shares of Class B common stock issued prior to the company's initial public offering. There will be no redemption rights or liquidating distributions with respect to the company's warrants, which will expire worthless. The company anticipates that the Public Shares, as well as the company's publicly traded units and warrants, will cease trading as of the close of business on December 21.

16:58 EST Westwood Holdings Group acquires Salient Partners for upfront payment of $35M - Westwood Holdings Group has acquired the asset management business of Salient Partners, L.P., a Houston-based asset management firm. As a result, Westwood has also acquired a significant minority stake, previously owned by Salient, in Broadmark Asset Management LLC. Broadmark is a San Francisco-based asset manager offering hedged equity strategies and serves as sub-adviser to a pair of seasoned mutual funds and separately managed accounts now offered by Westwood. This strategic acquisition increases Westwood's total assets under management by 33% to $16.3B, adding specialization and scale across Westwood's Multi-Asset, Real Assets and Alternative range of strategies. The Westwood, Salient and Broadmark portfolio management and distribution teams will remain unchanged. Westwood has acquired Salient's asset management business for an upfront payment of $35M in cash, subject to certain customary adjustments, including adjustments for working capital and client consents, with deferred payments of cash and equity of up to $25M over several years, upon satisfaction of certain revenue retention and growth targets. The transaction is expected to result in significant accretion to economic earnings per share. Westwood expects economic EPS accretion of approximately 100% in 2023, the first full year following the transaction closing.

16:16 EST Hyzon Motors receives noncompliance notification from Nasdaq - Hyzon Motors announced that it has received a notice from Nasdaq stating that because the company has not yet filed its quarterly report on Form 10-Q for the period ended September 30, the company remains in non-compliance with Nasdaq Listing Rule 5250, which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission.

15:35 EST Ranger Oil up 3% after report on exploring options

14:49 EST Avadel says Delaware Court ordered Jazz to delist REMS Patent from Orange Book - Avadel Pharmaceuticals (AVDL) announced that the United States District Court for the District of Delaware ordered Jazz Pharmaceuticals (JAZZ) to delist U.S. Patent No. 8731963, or the "REMS Patent," from the U.S. Food and Drug Administration's Orange Book. "With this decision, Avadel seeks to accelerate the FDA's final approval decision for Lumryz, a once-at-bedtime investigational formulation of sodium oxybate for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy," Avadel stated. "We are pleased with the court's decision in favor of delisting the REMS Patent from the FDA's Orange Book, potentially accelerating a final approval. Upon the delisting of the REMS Patent, we are prepared to work collaboratively with the FDA to move to a final approval decision for Lumryz," said Greg Divis, CEO at Avadel Pharmaceuticals. "We are fully committed to bringing Lumryz to all eligible people with narcolepsy and look forward to providing updates on our progress." The company added: "On July 18, 2022, Lumryz received tentative approval from the FDA, with potential final approval pending disposition of the REMS Patent. On October 25, 2022, a Markman hearing was held in which Avadel renewed its request for expedited consideration of its pending motion to have the REMS Patent delisted from FDA's Orange Book. The Delaware Court granted that request on October 28th and held a hearing on that motion on November 15, 2022. Earlier today, the Delaware Court issued its written opinion ordering Jazz to request delisting of the REMS Patent. With the issuance of this ruling, Avadel intends to seek final FDA approval for Lumryz upon removal of the REMS Patent from the FDA's Orange Book."

14:18 EST Commerce Department's NTIA has 'no objection' to FCC approving Tegna deal - In a letter sent to the FCC by a representative for the Department of Commerce, Andrew Coley, Office of Chief Counsel, stated: "This letter is in reference to the Federal Communications Commission's referral to the Chair of the Committee for the Assessment of Foreign Participation in the United States Telecommunications Services Sector, requesting the Committee's views on the above-captioned application. Pursuant to Executive Order 13913, the National Telecommunications and Information Administration informs you that the Committee has reviewed the application and has no recommendation at this time to the Commission approving the application and no objection to the Commission granting it. The Committee reserves the right to review any resulting authorization in the future to identify any additional or new risks to U.S. national security or law enforcement interests." Reference Link

13:21 EST Taylor Swift says 'assured' Ticketmaster could handle ticket demand - In a statement on Instagram Story, Taylor Swift said it was "excruciating" to "watch mistakes happen with no recourse" relating to the sale of her tickets on Live Nation Entertainment's Ticketmaster. "I'm not going to make excuses for anyone because we asked them, multiple times, if they could handle this kind of demand and we were assured they could," Swift wrote. The singer that it is "really difficult" for her to "trust an outside entity."

13:05 EST Live Nation drops 3% to $69.57 after NY Times report of DOJ investigation

13:02 EST Jazz announces FDA approval of sBLA for Rylaze dosing schedule - Jazz Pharmaceuticals announced the U.S. Food and Drug Administration approval of a supplemental Biologics License Application, or sBLA, to add a Monday/Wednesday/Friday intramuscular dosing schedule for Rylaze. Rylaze is approved for use in the U.S. as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia, or ALL, and lymphoblastic lymphoma, or LBL, in adult and pediatric patients one month or older who have developed hypersensitivity to E. coli-derived asparaginase. Rylaze was first approved in the U.S. in June 2021 under the FDA Real-Time Oncology Review program. The approval with a dosing schedule of 25 mg/m2 administered IM every 48 hours met the immediate patient need for a non-E.coli-derived asparaginase treatment option while the clinical trial was still ongoing to evaluate additional dosing and administration options. "With the addition of a Monday/Wednesday/Friday dosing schedule for Rylaze, patients will have another dosing option, which provides sustained asparaginase activity throughout the entire course of Rylaze treatment," said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals.

13:01 EST Baker Hughes reports U.S. rig count up 3 to 782 rigs

12:26 EST Tetra receives clarification request from Health Canada on REDUVO NDS - Tetra Bio-Pharma is providing its shareholders with a regulatory status update on the REDUVO New Drug Submission. On December 30, 2020, the Company submitted its first new drug submission for the REDUVO soft gel capsules to Health Canada to obtain approval and a drug identification number for the prescription drug. The last response to Health Canada was end of May 2022. On November 16, the Company received a Clarification Request from Health Canada regarding the product labels. The Company will be submitting the response to Health Canada within the allowed timeframe.

12:00 EST Perfumania falls -12.7% - Perfumania is down -12.7%, or -$1.26 to $8.69.

12:00 EST Natural Grocers falls -16.1% - Natural Grocers is down -16.1%, or -$1.93 to $10.02.

12:00 EST Atkore rises 14.3% - Atkore is up 14.3%, or $14.41 to $115.03.

11:32 EST Roku to cut about 200 employee positions in the U.S. - In a regulatory filing on Thursday, Roku approved a plan to reduce the company's headcount expenses by a projected 5% to slow down the company's 2023 operating expense growth rate due to current economic conditions. This will affect approximately 200 employee positions in the United States. The company estimates that it will incur non-recurring charges of approximately $28M-$31M in connection with the headcount reductions, primarily consisting of severance payments, notice pay, employee benefits contributions and related costs. The company expects that the majority of the restructuring charges will be incurred in the fourth quarter of fiscal 2022 and that the implementation of the headcount reductions, including cash payments, will be substantially complete by the end of the first quarter of fiscal 2023.

11:03 EST Calyxt reports completing first phase in palm oil research collaboration pact - Calyxt announced that it has successfully completed the first phase in its research collaboration agreement with "a leading global food ingredient manufacturer based in Asia" to develop an improved soybean capable of producing an oil as a commercial alternative to palm oil. As previously disclosed, the completion of this first milestone results in a cash milestone payment to Calyxt. Calyxt has begun the second and final phase of the research collaboration and expects to receive a final milestone payment upon completion. Calyxt anticipates completing the final phase in the first quarter of 2024. "We are proud of the progress we've made in this collaboration. The achievement builds on our expertise working with soybeans along with our team's innovation and collective drive to engineer plant-based solutions that address sustainability challenges for our customers," said Michael Carr, President and CEO of Calyxt.

10:39 EST 8i Acquisition 2, EUDA Health complete business combination - Last night, 8i Acquisition 2 (LAX) announced the completion of its business combination with EUDA Health (EUDA). The combined company will operate under the name "EUDA Health Holdings Limited" and will be led by Founder and Chief Executive Officer Dr. Kelvin Chen. Commencing at the open of trading on November 18, 2022, the combined company's ordinary shares and warrants will trade on Nasdaq Stock Market under the symbols "EUDA" and "EUDAW," respectively. The transaction was approved by LAX's stockholders at the special meeting held on November 10, 2022.

10:33 EST Cartesian Growth Corp trading resumes

10:00 EST Borr Drilling falls -9.7% - Borr Drilling is down -9.7%, or -49c to $4.58.

10:00 EST Farfetch falls -12.0% - Farfetch is down -12.0%, or -$1.10 to $8.04.

10:00 EST Foot Locker rises 14.7% - Foot Locker is up 14.7%, or $4.85 to $37.85.

09:54 EST Continental to integrate Ambarella's scalable system-on-chip family in ADAS - In the future, Continental (CTTAY) will offer Advanced Driver Assistance Systems, or ADAS, solutions based on the "CV3" artificial intelligence system-on-chip family from semiconductor company Ambarella (AMBA), the company announced. "The high-performance, power efficient and scalable SoC portfolio, which is built for ADAS applications, complements Continental's solutions for assisted driving and further advances vehicle automation. The more sensors are installed in a vehicle, the greater the amount of data collected to detect the environment. The joint solution with a centralized single-chip processing based on 5 nanometer technology enables the next generation of vehicles to process the environment perception of multiple sensors even quicker thanks to an increasing performance level. Sensor solutions include high-resolution cameras, radars, lidars as well as ultrasonic sensors. The integrated SoC enables early data fusion, in which the information from different sensors is superimposed simultaneously for various modalities such as emergency brake assist, parking or cruising," Continental stated. Reference Link

09:47 EST Natural Grocers falls -7.5% - Natural Grocers is down -7.5%, or -90c to $11.04.

09:47 EST Burlington Stores rises 8.9% - Burlington Stores is up 8.9%, or $13.46 to $164.33.

09:47 EST Foot Locker rises 15.8% - Foot Locker is up 15.8%, or $5.21 to $38.22.

09:41 EST Foot Locker says sustained momentum throughout Q3 - Says encouraged by business heading into holidays. Says continues to see results from WSS loyalty program. Says continues to deliberately pivot business offline. Says working to optimize supply chain. Says closing Wausau, Wisconsin distribution facility. Says opening new Reno, Nevada distribution center. Says sustained much of the momentum from back to school throughout the quarter. Says expects to achieve 9M in savings from cost optimization program in Q4. Says will not be providing quarterly guidance on an ongoing basis. Says there will be a 53rd week in 2023 year. Comments taken from Q3 earnings conference call.

09:33 EST TuanChe Ltd (ADR) trading halted, volatility trading pause

09:24 EST NeoGenomics, ImmunoGen launche new program for ovarian cancer patients - NeoGenomics (NEO) launched a novel biomarker testing program for patients with epithelial ovarian cancer, including primary peritoneal or fallopian tube cancers. Through the FR-ASSIST program, sponsored by ImmunoGen, Inc., (IMGN), EOC patients will have access to the FOLR1 IHC CDx test performed by NeoGenomics to measure the expression of a protein called folate receptor alpha. The FR-ASSIST program was launched in conjunction with the recent U.S. Food and Drug Administration's approval of ELAHERE, ImmunoGen's antibody-drug conjugate targeting FRalpha in patients with platinum-resistant EOC. The new testing program is sponsored entirely by ImmunoGen and provides eligible EOC patients with FRalpha-expression testing through NeoGenomics at no cost, regardless of insurance coverage or test results.

09:17 EST Muscle Maker launches vertical integration initiative with AGGIA - Muscle Maker announced its new vertical integration initiative by forming a new wholly owned subsidiary, Sadot LLC, and hiring AGGIA LLC to perform the day-to-day operations of the new subsidiary. AGGIA is an international consulting firm constituted of senior executives with significant backgrounds in the food and agri supply chain industries. AGGIA's team possesses expertise on moving various grains and other food products around the world. Sadot LLC will primarily participate in activities such as sourcing, distributing and production of agriculture products. A typical transaction consists of shipping grains via cargo ship from one country to another containing 25,000 to 70,000 metric tons of grains with values ranging between $5 million and $40 million dollars per shipment. These transactions could be thought of as "truckers of the seas" and an integral part of feeding the world. We have engaged AGGIA on a pay-for-performance basis. AGGIA only earns shares of Muscle Maker common stock if net income is generated by Sadot LLC. The shares of common stock are calculated by dividing the net income generated for an applicable quarter by a premium share price of $1.5625 per share. Over time, AGGIA can gain control of Muscle Maker's Board of Directors once $9.9 million in net income is generated by Sadot LLC. AGGIA may earn up to 14,424,275 shares of common stock, which would require Sadot LLC generating $22,537,929 in net income. Upon AGGIA earning the maximum amount of shares of common stock, if net income is generated, it shall be accrued as debt.

09:13 EST Vitru announces expiration, results of rights offering - Vitru announced that its previously announced rights offering has expired. A total of 926,206 of Vitru's nontransferable subscription rights were exercised in the Rights Offering, which will result in the issuance of 926,206 common shares of Vitru at U.S.$16.02 per common share, and raise gross proceeds of U.S.$14.8 million. After giving effect to the Rights Offering and the closing of the investment by Crescera on November 10, 2022, Vitru will have a total of 33,471,310 common shares issued and outstanding. The settlement of the Rights Offering is expected to occur on or around November 21, 2022. Pursuant to the Rights Offering, Vitru distributed nontransferable subscription rights to each holder of its common shares as of 5:00 p.m., Eastern Time, on October 21, 2022. The subscription rights were exercisable at any time during the subscription period, which commenced on October 24, 2022, and ended at 5:00 p.m., Eastern Time, on November 17, 2022. The unexercised subscription rights have now expired and have no value. Any excess subscription payments received by American Stock Transfer & Trust Company, LLC, Vitru's subscription agent for the Rights Offering, will be returned to the respective holders without interest.

09:08 EST Pitney Bowes announces 6.5% general rate increase for e-commerce services - Pitney Bowes announced a 6.5% general rate increase for e-commerce services effective January 1, 2023. The pricing program continues the company's commitment to providing ecommerce shippers with simple, easy to understand rates and services. The 6.5% GRI applies to the following services: standard delivery of parcels weighing one pound or more through the Pitney Bowes US domestic network; standard returns through the Pitney Bowes U.S. domestic network cross-border delivery services to more than 100 countries.

09:05 EST Greenpro Capital incubatee company Angkasa-X files for IPO - Greenpro Capital announced that its incubated company Angkasa-X, filed form F-1 Registration Statement for IPO in the US capital market. Angkasa-X obtained Network Facilities Providers and Network Service Providers licenses from Malaysia Regulator and filed for Advance Publication Information approval for the spectrum and frequencies of the proprietary design LEO Satellite to International Telecommunication Union. Greenpro owns 28 million shares in Angkasa-X.

09:04 EST XFuels announces Cycle Oil & Gas hires independent geologist Felton - Xfuels reports that Cycle Oil & Gas has hired an Independent Geologist, David Felton, to begin developing a drilling program on its 174-acre Hodges lease. The Hodges lease is located in Wichita County, Texas and sits atop the Mature K.M.A & Ellenberger reservoirs which have been drilled & produced since the 1930s. Through its Purchase of the Hodges lease in October 2022 from "Triple S Gas", Cycle owns full depth rights through its existing lease. Management has been encouraged by multiple offset wells being drilled by neighboring operators in recent months and thought it necessary to seek additional council to evaluate its properties. In addition, Cycle has already scheduled workovers for the existing shallower wells on the lease and is aiming to have them back online by the end of December. Felton is a seasoned Geologist and has been a member of the Association of Petroleum Geologists since 1978. During his career he has spent years as a well site geologist & well log analyst.

09:03 EST Marine Petroleum Trust cuts quarterly cash distribution to 24.4387c per unit - Payable on December 28 to unitholders of record on November 30. This distribution of 24.4387c per unit is lower than the 26.1822c per unit distributed last quarter. Volumes of both oil and natural gas produced this quarter decreased while the price realized on both oil and natural gas and included in this distribution have increased.

09:01 EST Bank7 raises quarterly dividend 33% to 16c per share - The dividend will be paid on January 5, 2023 to shareholders of record as of the close of business on December 23, 2022.

08:43 EST NextEra Energy Partners still sees 2023 adjusted EBITDA $2.22B-$2.42B - NextEra Energy Partners continues to expect 2023 run-rate for adjusted EBITDA of $2.22B-$2.42B and CAFD of $770M-$860M, reflecting calendar year 2024 expectations for the portfolio at year-end 2023.

08:37 EST NextEra Energy Partners still sees 2022 adjusted EBITDA $1.78B-$1.98B - NextEra Energy Partners continues to expect year-end 2022 run-rate adjusted EBITDA and CAFD in the ranges of $1.785B-$1.985B and $685M-$775M, respectively, reflecting calendar year 2023 contributions from the forecasted portfolio at the end of 2022. Continues to expect 12% to 15% growth per year in limited partner distributions per unit as being a reasonable range of expectations through at least 2025, subject to the usual caveats. NextEra Energy Partners expects the annualized rate of the 4Q22 distribution that is payable in February 2023 to be in a range of $3.17-$3.25 per common unit.

08:33 EST Venus Concept completes $6.72M private placement financing - Venus Concept announced that it has completed a non-brokered private placement of convertible preferred stock and common stock of the Company. Pursuant to the Private Placement, an aggregate of 3,185,000 Preferred Shares and 1,750,000 Common Shares were issued, resulting in aggregate gross proceeds to the Company of $6.72 million before offering expenses, which will be used for working capital and general corporate purposes. The Common Shares were issued at a price of $0.20 per share, and the Preferred Shares were issued at $2.00 per share. Each Preferred Share is convertible into 10 Common Shares at the option of the holder or at the option of the Company within 30 days following the earlier of the 30-trading day VWAP of the Common Shares exceeding $1.25 or the Company reporting two consecutive fiscal quarters of positive free cash flow. The Preferred Shares portion of the financing was led by the Company's existing investors: EW Healthcare Partners, Masters Special Situations, LLC and its affiliates, and HealthQuest Capital. The Common Shares portion of the financing was led by Rajiv De Silva, Chief Executive Officer of Venus Concept, Dr. Hemanth Varghese, President & Chief Business Officer of Venus Concept, and Dr. S. Tyler Hollmig, an independent director of Venus Concept.

08:32 EST MCI Capital commences cash tender offer for Atento shares - MCI Capital announced that it is commencing a cash tender offer to purchase up to 1,525,000 ordinary shares of Atento at a purchase price of $5.00 per share. If more than 1,525,000 shares are tendered in the tender offer, then, subject to the terms and conditions of the tender offer, MCI will purchase shares from shareholders who properly tender shares on a pro rata basis based on the aggregate number of shares tendered. The tender offer will be conditioned upon, among other things, a minimum of 775,000 shares being validly tendered and not withdrawn in accordance with its terms. The tender offer is scheduled to expire at 12:00 midnight at the end of the day on December 16, 2022, unless extended.

08:25 EST Global Tech Industries announces application for listing on Upstream - Global Tech Industries Group has begun the application process to list its shares on Upstream, a trading app for digital securities and NFTs powered by Horizon Fintex and MERJ Exchange Limited. The proposed listing on Upstream is designed to provide the Company the opportunity to access an international, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, potentially unlocking liquidity and enhancing price discovery. Approval to be listed on Upstream is subject to approval by MERJ. However, as an existing OTCQB company, GTII may be eligible for an expedited listing process

08:13 EST Novavax's COVID-19 vaccine authorized in Canada as booster in adults - Novavax announced that Health Canada has granted expanded authorization for Nuvaxovid COVID-19 Vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 as a homologous booster in adults aged 18 and older. The expanded authorization was based on data from a Phase 2 trial conducted in South Africa and from the Prevent-19 Phase 3 trial conducted in the U.S. and Mexico. The third booster dose produced increased immune responses to levels comparable to or exceeding those associated with protection against COVID-19 in Phase 3 clinical trials. In the trials, following the booster, local and systemic reactions had a median duration of approximately two days. Novavax' vaccine has been authorized as a heterologous and homologous booster in the U.S., European Union, U.K., Japan, Australia, New Zealand, and Switzerland, and a number of other countries have policy recommendations allowing use of the vaccine as a heterologous or homologous booster dose. Novavax has ongoing trials to further explore the vaccine's immunogenicity and safety as a heterologous booster.

08:11 EST electroCore announces gammaCore Sapphire issues CNK in Belgium - electroCore announced that gammaCore Sapphire has been issued a National Code Number, CNK, in Belgium. CNK numbers are unique product code identifiers allocated by the Belgian Pharmaceutical Association for products and medicines commercially available from pharmacies throughout Belgium and enables product recognition throughout the pharmaceutical network. "This positive news will allow us to provide patients with a convenient way to easily access gammaCore at their local pharmacy," mentioned Iain Strickland, Senior Vice President Global Sales and Strategy at electroCore. "We have taken a big step forward in making our therapy more widely available throughout Europe. The publication of the CNK code, makes gammaCore recognized within the Belgian pharmaceutical database and therefore available via any pharmacy in Belgium."

08:08 EST SurgePays closes $25M senior credit facility - SurgePays announced it has closed on a $25 million senior secured credit facility from Affordable Connectivity Financing V. Approximately $15 million of financing was provided at closing. The credit facility, an Installment Sale Agreement with ACF V, is a structured credit, non-dilutive structure without warrants, convertibility or stock issued as part of the transaction. An Installment Sale Agreement is a unique short-term liability that provides for repayment over the subscriber life in a fashion that should allow SurgePays to grow its subscriber base in a cash flow positive manner.

08:07 EST InMed Pharmaceuticals announces $6M private placement - InMed Pharmaceuticals announced that it has entered into a securities purchase agreement with two healthcare-focused institutional investors for the issuance and sale of 1,818,185 of its common shares at a purchase price of $3.30 per share in a private placement priced at-the-market under Nasdaq rules. In addition, the Company has agreed to issue to the investors in the offering unregistered preferred investment options to purchase up to an aggregate of 3,272,733 common shares. The aggregate gross proceeds to the Company from the private placement is expected to be approximately $6 million. The offering is expected to close on or about November 21, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to continue pipeline development of its pharmaceutical drug candidates, advance manufacturing know-how of cannabinoids and cannabinoid analogs, support intellectual property development and other commercial activities, and for general working capital purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The unregistered investment options to be issued in the offering will be exercisable immediately upon issuance at an exercise price of $3.044 per share and will expire seven years from the date of issuance. In addition, the investors in the private placement agreed to cancel preferred investment options to purchase up to an aggregate of 1,382,490 common shares of the Company which were previously issued to the investors.

08:06 EST TFF Pharmaceuticals prices $10.675M offering of common stock, warrants - TFF Pharmaceuticals announced that it has priced a $10.675 million underwritten offering of 9,282,609 shares of its common stock and warrants to purchase up to 4,641,305 shares of common stock. The warrants are being sold at the rate of one warrant for every two shares of common stock. The public offering price, before the underwriters' discount and commissions, for each share of common stock and accompanying warrant is $1.15. All of the securities in the offering were sold by the TFF Pharmaceuticals, Inc. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 15% of the number of shares and warrants offered at the public offering price, less underwriting discounts and commissions. The offering is expected to close on Tuesday, November 22, 2022. TFF Pharmaceuticals intends to use the net proceeds from the offering for clinical trials, research and development, working capital and general corporate purposes. JonesTrading Institutional Services LLC acted as the sole book-running manager and Newbridge Securities Corporation acted as lead manager for the offering.

08:05 EST Turquoise Hill acknowledges announcement made by Rio Tinto - Turquoise Hill (TRQ) acknowledged the announcement by Rio Tinto (RIO) that it has terminated the previously announced agreements between Rio Tinto and certain shareholders of the company related to Pentwater Capital Management and SailingStone Capital Partners and that it has made certain irrevocable commitments for the benefit of all minority shareholders. Rio Tinto's termination of the agreements and its decision to provide the irrevocable commitments described below followed discussions between Rio Tinto and the special committee of the board of directors of the company to resolve minority shareholder and public interest concerns with respect to the specific dissent and dispute resolution terms provided for in the agreements to the named shareholders. The company said, "The Company intends to apply to the Supreme Court of Yukon (the "Court") for an amended interim order to, among other things, set a new date for the special meeting of Turquoise Hill shareholders (the "Special Meeting") to consider and, if deemed advisable, approve the plan of arrangement pursuant to which, subject to the satisfaction or waiver of all applicable conditions precedent, Rio Tinto will acquire the approximately 49% of the issued and outstanding common shares of Turquoise Hill that Rio Tinto and its affiliates do not currently own for C$43.00 per share in cash (the "Arrangement"). The Company will provide further disclosure to Turquoise Hill shareholders, including with respect to the date of the Special Meeting, following the receipt of the amended interim order. Turquoise Hill shareholders are not required to take any action at this time. In its announcement, Rio Tinto has made certain irrevocable commitments for the benefit of all Turquoise Hill minority shareholders. Specifically, Rio Tinto has committed to do the following: Waive the 12.5% dissent condition in respect of the Arrangement, provided that Turquoise Hill shares for which dissent is validly exercised do not exceed 17.5% of Turquoise Hill shares outstanding; Pay C$34.40 per share (the "Upfront Payment") to any Turquoise Hill shareholder who validly dissents and elects to receive such amount (an "Electing Shareholder"), within two business days of the effective date of the Arrangement (the "Effective Date"); Pay to an Electing Shareholder interest at the Canada 1 Year Treasury Bill Yield on any balance of "fair value" that becomes payable under the dissent process over and above the Upfront Payment up to C$43.00 per share calculated from the Effective Date to the date of payment, provided that no other interest shall be payable to an Electing Shareholder in respect of any fair value payment; and Allow any oppression claims by any Turquoise Hill minority shareholders, including Electing Shareholders, against Turquoise Hill, Rio Tinto or their respective affiliates, to survive the Arrangement and be pursued following the Effective Date, where such claims are served on or provided to Turquoise Hill and Rio Tinto no later than seven days following the Effective Date. Under the dissent procedures, there is no floor or minimum to the determination of "fair value" and no assurance that dissenting shareholders will receive the full C$43.00 for their shares. Pursuant to the Agreements, the Named Shareholders had agreed to withhold their votes in connection with the Arrangement in exchange for certain commitments by Rio Tinto with respect to the private resolution of dissent and other claims of the Named Shareholders. As a result of the termination of the Agreements, Rio Tinto is no longer committed to providing private dispute resolution procedures to the Named Shareholders in connection with their dissent and other claims. All minority shareholders of Turquoise Hill (including the Named Shareholders) may rely on the dissent proceedings provided for under Section 193 of the Business Corporations Act (Yukon), as modified by the interim order and plan of arrangement pertaining to the Arrangement, in order to exercise their dissent rights. The terms of the dissent procedures are further described in the Company's management information circular dated September 27, 2022 (the "Circular") and associated form of proxy and letter of transmittal (collectively, the "Meeting Materials"). The Meeting Materials are filed and available under Turquoise Hill's profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. It is recommended that minority shareholders seek independent legal advice if they wish to exercise their dissent rights. As a result of the termination of the Agreements, there is no assurance that any of the Named Shareholders will continue to withhold their vote or whether any of them will vote for or against the Arrangement."

08:02 EST Belite Bio finalizes Phase 3 trial plans for dry AMD treatment - Belite Bio announced that, following discussions with the FDA, it has finalized the study design for its planned Phase 3 clinical trial to evaluate efficacy and safety of Tinlarebant in patients with geographic atrophy associated with Dry AMD. "We are very excited to initiate our Phase 3 advanced Dry AMD study to bring forward an early intervention, once-a-day oral treatment for patients suffering from visual loss due to Dry AMD. The safety and efficacy of Tinlarebant is currently being evaluated in a Phase 2 study and a Phase 3 study in patients affected by STGD1. Considering that a common cause of disease progression in both GA and STGD1 is characterized by the aberrant accumulation of cytotoxic byproducts of vitamin A, we are optimistic for a positive outcome for Tinlarebant in GA patients," said Dr. Tom Lin, CEO of Belite Bio. Phase 3 Advanced Dry AMD Study Outline: 2-year prospective, randomized, double-masked, placebo-controlled study designed to assess the efficacy and safety of daily oral Tinlarebant. Enrollment expected to begin in the first half of 2023 of at least 300 GA patients across multiple centers globally. The primary endpoint will be the change in GA lesion size from baseline to month 24, compared to placebo. An interim analysis of efficacy and safety is expected to be conducted at the mid-point of the study.

07:51 EST LyondellBasell moving forward with advanced recylicng plant in Germany - LyondellBasell has made a decision to move forward with engineering to build an advanced recycling plant at its Wesseling, Germany, site. Using LyondellBasell's proprietary MoReTec technology, this commercial scale advanced recycling plant would convert pre-treated plastic waste into feedstock for new plastic production. The final investment decision is targeted for the end of 2023. The German Joint Venture Source One Plastics will provide plastic waste feedstock to the plant. Source One Plastics is planning to build a facility designed to recycle the amount of plastic packaging waste generated by approximately 1.3 million German citizens per year. The start-up of the MoReTec advanced recycling plant is planned for end of 2025 with a capacity of 50,000 tons per year. The feedstock produced will be converted at the LyondellBasell Wesseling site into new CirculenRevive polymers for use in applications such as food packaging and healthcare products.

07:42 EST Argo Group provides update on strategic review, proxy contest - Argo Group announced that it has filed an investor presentation with the U.S. Securities and Exchange Commission in connection with its 2022 annual meeting of shareholders, which is scheduled to be held on December 15. The presentation is available on the 2022 annual meeting shareholder materials section of Argo's investor relations site. The company issued the following statement: "Over the past three years, Argo has successfully transformed the Company into a leading U.S. specialty insurer. Since we announced the sale of our Lloyd's Syndicate 1200 to Westfield in September 2022, our stock has outperformed our insurance peers, which we believe indicates the stability of our reshaped business and confidence in our improved operating model. This effort has been further advanced by the Board's ongoing strategic review process to evaluate a range of alternatives, including a potential sale of the whole Company. The process is being overseen by a Strategic Review Committee, which is composed of seasoned directors who collectively have strong M&A, capital markets and regulatory experience, and are well-suited to make recommendations to the entire Board. To ensure shareholder alignment, the Board appointed J. Daniel Plants, Chief Investment Officer of Voce Capital Management LLC, Argo's largest shareholder with approximately 9.5% of the Company's shares, to the Board and as Chair of the Strategic Review Committee. The Board is open to considering any and all credible proposals to maximize shareholder value, and as previously noted, Argo's financial advisor has conducted exhaustive outreach to more than 80 parties. Unfortunately, despite the recent actions to position Argo for success, one of our shareholders, Capital Returns Master, Ltd., has initiated a proxy contest to replace two of Argo's directors - Bernard Bailey and Al-Noor Ramji - with its own candidates, Ronald Bobman and David Michelson. Our Board is highly engaged, having met more than 60 times in 2022 and more than 30 times since publicly announcing our strategic review process, and is laser-focused on ensuring the Company is on the right path to maximizing value for shareholders. We believe this is contrary to Mr. Bobman's actions. The Board and management have met with Mr. Bobman several times to discuss his views, and throughout these interactions Mr. Bobman has made numerous naive, and in some cases factually false, criticisms that do not reflect the reality of Argo's actions. At the same time, despite repeated invitations, Mr. Bobman has failed to offer any tangible recommendation or suggestion for creating shareholder value beyond launching a strategic alternatives process - which the Board already publicly announced and is now in the latter stages of conducting. Thus, we are left to believe that Mr. Bobman's primary objective is to attract attention to his fund through publicizing his criticisms. We believe the ongoing strategic review process is best overseen by the current Argo Board of Directors and its Strategic Review Committee, not Capital Returns' nominees. It is our strong view that appointing either of Capital Returns' nominees would result in a loss of superior talent and experience, a degradation in the quality of Board dialogue and could delay or hinder the strategic review just as it enters its most critical phase."

07:35 EST Biotricity provides update on operational, expansion strategy - Biotricity provided a recap of its recent operational and corporate activities and discussed the Company's distribution strategy for the second half of FY 2023 ending March 31, 2023. Recent Operating and Corporate Highlights: Recently signed a distribution agreement with a Top 10 US medical distributor for sales of its flagship cardiac monitoring solutions, Bioflux and Biotres. This partnership further expands the Company's commercialization opportunities to reach its target total addressable market of approximately $6 billion; Continued expansion of Biotricity's sales network, combined with a 95% customer retention rate, that together drive Biotricity's growing base of recurring revenue; The Company's Bioheart personal cardiac monitor won TIME's Best Inventions of 2022; Awarded $250K NIH grant from the National Heart, Blood, and Lung Institute for AI-enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure; Surpassed 2 billion recorded and analyzed heartbeats for atrial fibrillation; Launched proprietary Biocare cardiac disease management solution after two successful pilots at Oklahoma & Kentucky clinics. Looking ahead, Biotricity's strategy is to strengthen cash flow, reduce capital expenditures, capture market share of this fast-growing marketplace, drive top-line growth and enhance its industry position through unrivalled customer and physician/partner service. As such, the Company is cross- and up-selling its full suite of cardiac monitoring products to its customer base to position itself as the leading provider of a complete, AI-enabled, cloud-based cardiac ecosystem -- creating a deeper, more impactful relationship with healthcare providers and patients. Additionally, having established its product and technological position, Biotricity is initiating a far more extensive distribution strategy focused on partnering with medical device distributors with large salesforces to create a much wider, branded footprint within the market. Upcoming Catalysts and Growth Drivers: Broadening the distribution and reach of its comprehensive suite of cardiac care management products and services; Additional agreements with hospitals, vendors and medical device distribution outlets; New product developments anticipated within the next several months; Expected continued revenue growth while reducing capital expenses thus advancing towards profitability,

07:32 EST Gaotu Techedu receives NYSE non-compliance letter - Gaotu Techedu has received a letter from the NYSE notifying that the company is below compliance standards due to the trading price of its ADSs being less than $1.00 over a consecutive 30 trading-day period. As of November 15, 2022, the 30 trading-day average price of the company's ADSs was $0.90. The company must bring its share price and average share price back above $1.00 by six months following receipt of the notification. In the event that at the expiration of the six-month cure period, both a $1.00 closing share price on the last trading day of the cure period and a $1.00 average closing share price over the 30 trading-day period ending on the last trading day of the cure period are not attained, the NYSE will commence suspension and delisting procedures. The company intends to monitor the market conditions of its listed securities and is still considering its options to cure this deficiency.

07:31 EST KemPharm receives FDA Orphan Drug Designation for SDX - KemPharm announced that the U.S. Food and Drug Administration, FDA, has granted the Orphan Drug Designation to serdexmethylphenidate, SDX, KemPharm's proprietarf d-methylphenidate, for the treatment of idiopathic hypersomnia (IH), a rare neurological sleep disorder. KemPharm expects to initiate a Phase 2 clinical trial of KP1077 in patients with IH prior to year-end 2022 and a second trial in patients with narcolepsy in 2023. "We appreciate the FDA's decision to grant Orphan Drug Designation to SDX for IH, a rare sleep disorder characterized by multiple, debilitating symptoms for which few treatment options exist," stated Travis Mickle, Ph.D., President and Chief Executive Officer of KemPharm. "This regulatory milestone comes at an important juncture in the ongoing development of KP1077 as we prepare to initiate the Phase 2 clinical trial in IH before year-end 2022. We believe KP1077 could provide an improved treatment option for patients with IH and other sleep disorders by addressing the most debilitating symptoms of IH, including excessive daytime sleepiness, extreme difficulty waking up (sleep inertia), severe "brain fog," and falling asleep unintentionally and/or at inappropriate times, even after adequate or prolonged nighttime sleep."

07:08 EST Intensity Therapeutics' INT230-6 shows potential in metastatic sarcoma survival - Intensity Therapeutics announced that data from its open-label phase 1/2 study of novel lead asset, INT230-6, as a monotherapy or in combination with ipilimumab in adult subjects with metastatic sarcomas, will be presented at the Connective Tissue Oncology Society Annual Meeting in Vancouver. Dosing with INT230-6 resulted in a median overall survival of 715 days vs. 205 days on historical sarcoma control. "Preliminary data suggests that INT230-6, as a monotherapy or in combination with the immune checkpoint blocker ipilimumab, demonstrates direct tumor killing in soft tissue sarcoma (STS) and elicits an anti-cancer immune response within the injected tumor," stated principal investigator Matthew Ingham. "To date, INT230-6 treatment related adverse events are mostly low grade and the drug is well-tolerated either as a monotherapy or in combination with ipilimumab. Additionally, in patients who had 40% or more of their tumor burden treated with INT230-6, an exploratory analysis showed that overall survival was improved when compared to historical benchmarks for this patient population." CEO Lewis Bender added, "The compelling safety and efficacy results from use of our drug in treating such a deadly and hard-to-treat cancer as soft tissue sarcomas underscore the potential of this treatment. The promising data supports our belief that INT230-6 could show clinical benefit with lower levels of off-target side effects compared to standard chemotherapies. We have designed a randomized phase 3 trial protocol to evaluate INT230-6 versus standard of care in patients with advanced soft tissue sarcomas and look forward to initiation of the study."

07:08 EST Foot Locker jumps 17% to $38.80 after Q3 results beat, FY22 guidance raised

07:05 EST Luckin Coffee releases 2020-2022 corporate governance report - Luckin Coffee Inc. ("Luckin Coffee" or the "Company") (OTC: LKNCY) today released its Corporate Governance Report for the period January 1, 2022 through September 30, 2022, highlighting the Company's focus on corporate innovation and sustainable development, and is aimed at helping Luckin Coffee stakeholders better understand its operations and long-term strategic priorities. The report discloses information and developments on Luckin Coffee's strengthened corporate governance concepts, structure and practices. "We hope our experiences and reflections can build a solid foundation for Luckin Coffee to enter the next stage. We have high expectations that Luckin Coffee will create greater value for society," said Dr. Jinyi Guo, Chairman and Chief Executive Officer of Luckin Coffee. Below are some of the key highlights of our corporate governance initiatives and practices, as outlined in the report: Introduced the Company's core values of integrity, craftsmanship, innovation, ownership and cooperation; Reshaped corporate governance structure to enable a multi-faceted supervision system with clear segregation of duties; Implemented a "Three Lines of Defense" risk management structure which utilizes a cross-organizational, multi-functional audit and control mechanism; Established Sustainable Development Committee and introduced an environmental, social and governance framework; Implemented strict quality-control measures, guided by Food Safety and Quality Control Committee which identifies, assesses, mitigates and continuously monitors all product quality-related risks; Developed a stringent raw material management system to ensure product quality and safety and integrate ethical supply chain practices; Conducted multiple training programs to support the diversity and the rapid growth of the Company's personnel; nearly 50% of full-time staff are women.

07:04 EST Orthofix, SeaSpine report John Bostjancic will serve as CFO for combined company - Orthofix (OFIX) and SeaSpine (SPNE) announced that John Bostjancic will serve as CFO for the new combined company, effective upon the completion of their pending merger. Bostjancic currently serves as the CFO and COO of SeaSpine, roles he has held since 2015 and 2022 respectively. Doug Rice, current CFO of Orthofix, will provide post-closing assistance with the integration activities during a transition period. As announced on October 11, Orthofix and SeaSpine agreed to combine in an all-stock merger of equals. The transaction is expected to close in the first quarter of 2023 subject to Orthofix and SeaSpine shareholder approvals and other customary closing conditions.

07:02 EST Cloopen granted extension by NYSE for filing 2021 annual report - Cloopen received a letter from NYSE Regulation indicating that NYSE's Listings Operations Committee agreed to provide the company with an additional trading period through May 17, 2023, subject to reassessment on an ongoing basis, to complete and file the company's annual report for fiscal year 2021 with the SEC and any subsequent delayed filings. NYSE Regulation will closely monitor the company's progress with the milestones and timing submitted to the NYSE. Failure to achieve these interim milestones could result in accelerated trading suspension prior to the end of the May 17, 2023 trading period. In addition, in the event that the company does not complete the filing of the 2021 Annual Report and any subsequent delayed filings with the SEC by the end of the maximum 12-month cure period on May 17, 2023, the NYSE will move forward with the initiation of suspension and delisting procedures.

07:02 EST Orthofix, SeaSpine appoints Bostjancic as CFO for combined company - Orthofix (OFIX) and SeaSpine (SPNE) announced that John Bostjancic will serve as Chief Financial Officer, CFO, for the new combined company, effective upon the completion of their pending merger. Bostjancic currently serves as the CFO and Chief Operating Officer of SeaSpine, roles he has held since 2015 and 2022 respectively. Doug Rice, current CFO of Orthofix, will provide post-closing assistance with the integration activities during a transition period.

06:49 EST Canada Goose launches share repurchase program - Canada Goose announced that the Toronto Stock Exchange has approved a normal course issuer bid providing for the purchase for cancellation of up to 5,421,685 subordinate voting shares of Canada Goose over the twelve-month period commencing on November 22, 2022 and ending no later than November 21, 2023. This represents approximately 10% of the 54,216,852 subordinate voting shares comprising the public float as at November 10, 2022. Purchases made under an issuer bid exemption order will be at a discount to the prevailing market price as per the terms of the order. Canada Goose will otherwise be allowed to purchase daily, through the facilities of the TSX, a maximum of 86,637 subordinate voting shares representing 25% of the average daily trading volume. Canada Goose is allowed to purchase up to 10% of its Public Float through the facilities of the NYSE and other U.S.-based trading systems as part of any NCIB implemented in the 36 months following the date of the decision.

06:34 EST BitNile subsidiary to acquire assets of Circle 8 Crane Services for $40M - BitNile Holdings announced that Circle 8 Newco, a newly formed indirect subsidiary of Ault Alliance, a wholly owned subsidiary of the company, has entered into an asset purchase agreement with Circle 8 Crane Services, providing for the acquisition of substantially all of Circle 8's operating assets and recapitalization of the business into Circle 8 Newco for an aggregate consideration of approximately $40M. The acquisition will be funded with $16M in cash and approximately $24M of asset-based debt will be assumed. Circle 8 is a crane rental and lifting solutions provider founded in 2007 and headquartered in Corpus Christi, TX with multiple locations throughout the South Central region of the U.S. It maintains a large modern fleet of mobile cranes for its customers' heavy lifting needs. In particular, Circle 8 provides crane operators, engineering, custom rigging and transportation services for oilfield, construction, commercial and infrastructure markets. Circle 8 maintains an industry leading safety record.

05:34 EST Chubb receives regulatory approval to increase ownership in Huatai to 83.2% - Chubb announced that it has received regulatory approval from the China Banking and Insurance Regulatory Commission to increase the company's ownership in Huatai Insurance Group Company from 47.3% to 83.2%. Huatai is the holding company of a number of subsidiary companies including Huatai Property & Casualty Insurance Company, Huatai Life Insurance Company, and Huatai Asset Management Company. Huatai's insurance operations have more than 700 branches, 23,000 agents and approximately 19M customers in China. Huatai Asset Management has over $100B in assets under management and is licensed to manage institutional, pension and retail mutual fund businesses. As of September 30, Huatai Group had assets of over $10B and equity of over $2B. In 2021, Huatai had total revenue of over $2B.

05:18 EST WISeKey reports Semiconductors IoT segment returns to pre-COVID levels - WISeKey announced that its Semiconductors IoT segment has returned to pre-COVID levels and its FY22 revenue is expected to be approximately $22.7M, representing an increase of over 34% as compared to FY 2021. This trend is projected to continue in 2023 and the company expects revenue for the year to increase over 40%, and reach record levels, due to higher semiconductors demand and new contracts signed to secure medical equipment, drones, routers, batteries, and smart meters. The expected increase in FY22 revenue is mainly linked to the U.S. and EU markets with some wins in Japan and Taiwan. Recently WISeKey secured several major wins for its microchip semiconductor based IoT technology, anti-counterfeiting, brand protection, and secure access products with leading providers of networking equipment, medical devices, routers, and smart building solutions. WISeKey's semiconductor segment experienced growth during the year, despite COVID related supply chain disruptions which resulted in global semiconductor manufacturing shortages and significantly impacted the global economy and markets. Regardless of these shortages which are expected to continue through 2024, during the year WISeKey was able to successfully navigate and overcome these extraordinary challenges, while 2023 is expected to be a fully transformative year.

05:10 EST WeTrade to seek out strategic expansion in hospitality, residential sectors - WeTrade announced that the company intends to seek out strategic expansion in hospitality and residential sectors. Since the company believes that the two markets are likely to recover significantly as China eases its COVID restrictions, it plans to introduce its YCloud system to these two markets to further expand the company's business scope.